Bayer's Debt Clock Runs Faster Than Its Courtroom Clock

Bayer cut its year-end net debt target to EUR 29-30 billion as a St. Louis judge weighs final approval of the USD 7.25 billion glyphosate settlement.

Bayer has quietly improved the arithmetic that governs its balance sheet, trimming its year-end net financial debt target to EUR 29–30 billion from a previous range of EUR 32–33 billion. The revision, disclosed through the company's investor relations channel, leaves every other line of the annual guidance untouched. For a conglomerate still carrying the balance-sheet scar tissue of the Monsanto acquisition, that EUR 3 billion of breathing room is anything but a footnote.

The operational engine behind the cleaner outlook was visible in the second quarter. Group revenue reached EUR 10.87 billion, up 1.2% on a reported basis and 2.2% once currency and portfolio effects are stripped out. Adjusted EBITDA advanced 1.9% to EUR 2.14 billion. Management's full-year targets — adjusted EBITDA of EUR 9.6–10.1 billion and core earnings per share of EUR 4.30–4.90 — remain intact.

A Split Verdict Inside the Portfolio

Crop Science did the heavy lifting, lifting its adjusted result by 30.2% and cementing its role as the group's growth motor. Pharma moved the other way, slipping 3.6% in the quarter, though the cancer drug Nubeqa provided a counterweight with EUR 820 million in sales. Research delivered its own arguments: the heart medication Kerendia hit the primary endpoint in the Phase III FIND-CKD trial for non-diabetic chronic kidney disease and secured EU approval for heart failure with a left ventricular ejection fraction of 40% or above. None of that is baked into current guidance, yet it points toward a pharma unit less dependent on a handful of products.

Cash is also arriving from an unexpected direction. Bayer and Corteva settled their Agrobacterium licensing dispute earlier this year, with Corteva paying a total of USD 610 million. Roughly EUR 546 million of that landed in the first quarter; the remainder falls due by September 15.

Judith Hartmann took over as CFO from the retiring Wolfgang Nickl on June 1, and the more ambitious deleveraging targets are now hers to execute.

The Courtroom That Sets the Price Tag

The balance-sheet story collides with a St. Louis courtroom on Monday, when Judge Timothy Boyer weighs final approval of the USD 7.25 billion settlement announced in February. The hearing itself is familiar ground — an earlier procedural session knocked 1.7% off the share price roughly two weeks ago — but the newly surfaced mechanics of the payout structure are what matter now.

The deal covers about 65,000 U.S. claims tied to non-Hodgkin lymphoma and exposure to the herbicide before February 17, 2026, whether or not a diagnosis has been made. Payments are tiered: average awards run from roughly USD 10,000 to USD 165,000 depending on age, occupational exposure and how aggressive the disease is. In the top bracket — occupationally exposed claimants under 60 with an aggressive course — the points system can push payouts as high as USD 198,000. At the other end sit Quick-Pay tiers with fixed amounts of USD 6,000 to USD 14,500, plus a limited-evidence category worth just USD 150. Claimants already diagnosed get 180 days after final approval to register.

That ladder matters because USD 7.25 billion will not be spread evenly. A large share of cases should land in the lower and middle rungs, making the financial exposure more calculable than a flat settlement would suggest. The opt-out deadline for claimants who preferred to sue individually expired on June 4, meaning participation is largely locked in before Boyer rules.

Two Clocks, One Stock

The shares closed Friday at EUR 48.19, down 0.6% on the day and about 1.3% over the week. That leaves the stock roughly 11% below its 52-week high of EUR 53.86, set in July, though still far above the EUR 25.78 low of last November. Over twelve months the equity has gained 67%, and it is up 30% year to date — a run that suggests much of the legal risk is already discounted. The muted reaction to earlier procedural steps implies the market broadly expects approval.

Should Boyer sign off, a central overhang that has weighed on Bayer for years would be retired. A rejection or delay would raise fresh questions about the provisioning math, particularly for the thousands of claims covered by the settlement that have yet to be diagnosed.

The remainder of the Corteva payment falls due on September 15 — one day after the Missouri hearing. Two clocks, in other words, are ticking toward the same mid-September window: one measuring how fast Bayer can shed debt, the other measuring how much its legal legacy will finally cost.